Patient Square Capital LP Portfolio Holdings

Patient Square Capital LP

  • $374 Billion
  • Q3 2025

Patient Square Capital LP has filed its 13F form on November 10, 2025 for Q3 2025 where it was disclosed a total value porftolio of $374 Billion distributed in 24 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Roivant Sciences Ltd. with a value of $189B, Insmed Inc with a value of $47B, Eye Point Pharmaceuticals, Inc. with a value of $14.4B, Abivax Sa with a value of $12.9B, and Cidara Therapeutics Inc with a value of $11.6B.

Examining the 13F form we can see an increase of $96.5B in the current position value, from $277B to 374B.

Patient Square Capital LP is based out at Menlo Park, CA

Below you can find more details about Patient Square Capital LP portfolio as well as his latest detailed transactions.

Portfolio value $374 Billion
Healthcare: $329 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$14.3B
$189 Billion 50.51% of portfolio
12,480,000
Q4 2024 Added 2.06%
$26.2B
$47 Billion 12.57% of portfolio
326,400
Q3 2025 Reduced 9.03%
$404M
$14.4 Billion 3.85% of portfolio
1,011,839
Q3 2025 Reduced 25.21%
Abivax Sa
-
$12.9 Billion 3.45% of portfolio
-
Q3 2025 New
Cidara Therapeutics Inc
-
$11.6 Billion 3.1% of portfolio
-
Q3 2025 Added 706.67%
$50.2B
$11.4 Billion 3.06% of portfolio
15,500
Q3 2025 Reduced 46.55%
$1.84B
$9.1 Billion 2.43% of portfolio
400,000
Q3 2025 Reduced 60.78%
$795M
$8.62 Billion 2.3% of portfolio
345,381
Q3 2025 Added 41.39%
$875M
$8.36 Billion 2.24% of portfolio
715,000
Q3 2025 Reduced 12.56%
$2.63B
$7.64 Billion 2.04% of portfolio
104,262
Q3 2025 Reduced 8.11%
$2.39B
$5.37 Billion 1.44% of portfolio
133,827
Q3 2025 Reduced 4.23%
$3.55B
$5.24 Billion 1.4% of portfolio
92,592
Q3 2025 Reduced 33.86%
Enliven Therapeutics Inc
-
$5.13 Billion 1.37% of portfolio
-
Q3 2025 Added 2.03%
Dianthus Therapeutics Inc
-
$4.92 Billion 1.32% of portfolio
-
Q3 2025 New
$1.38B
$4.94 Billion 1.32% of portfolio
100,000
Q3 2025 New
Disc Medicine Inc
-
$4.89 Billion 1.31% of portfolio
-
Q2 2025 Reduced 10.84%
$743M
$4.3 Billion 1.15% of portfolio
316,312
Q3 2025 New
$603M
$4.04 Billion 1.08% of portfolio
437,237
Q3 2025 Added 6.05%
$177M
$3.7 Billion 0.99% of portfolio
2,981,396
Q3 2025 Added 13.15%
Assembly Biosciences Inc
-
$3.46 Billion 0.93% of portfolio
-
Q3 2025 New
Avalo Therapeutics Inc
-
$1.27 Billion 0.34% of portfolio
-
Q3 2025 New
Perspective Therapeutics Inc
-
$1.2 Billion 0.32% of portfolio
-
Q3 2025 New
$423M
$1.16 Billion 0.31% of portfolio
845,000
Q3 2025 Added 18.02%

Summary

  • Portfolio
  • No. of Stocks 24
  • Current Value $374 Billion
  • Prior Value $277 Billion
  • Filing
  • Period Q3 2025
  • Filing Date November 10, 2025
  • Form Type 13F-HR
  • Activity in Q3 2025
  • New Purchases 8 stocks
  • Additional Purchases 6 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 8 stocks
Track This Portfolio

Track Patient Square Capital LP Portfolio

Follow Patient Square Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Patient Square Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Patient Square Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email